Get the Stockscreener App
2.29
0.71%
-0.0164
After Hours:
2.29
Immunitybio Inc stock is traded at $2.29, with a volume of 6.84M.
It is down -0.71% in the last 24 hours and up +6.51% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.3064
Open:
$2.31
24h Volume:
6.84M
Relative Volume:
0.68
Market Cap:
$2.26B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.3608
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-2.97%
1M Performance:
+6.51%
6M Performance:
-21.03%
1Y Performance:
-49.89%
1-Day Range:
$2.2433
$2.32
1-Week Range:
$2.06
$2.46
52-Week Range:
$1.83
$5.12
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.29 | 2.27B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Insider Monkey
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - Insider Monkey
10 Stocks Racking Up Big Gains - Insider Monkey
ImmunityBio Stock Boosted by Rising Demand for ANKTIVA and Positive Clinical Trials - StocksToTrade
ImmunityBio’s Strong Market Position Boosted by Recent Innovations - timothysykes.com
HEIGHTS CAPITAL MANAGEMENT, INC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
ImmunityBio’s Clinical Advances and Sales Boost Highlight Market Optimism - StocksToTrade
ImmunityBio Stock (IBRX) Opinions on Q3 Revenue Growth - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Some Confidence Is Lacking In ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
ImmunityBio’s Strategic Developments and Financial Growth Fuel Optimism - timothysykes.com
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning? - ts2.tech
Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London - simplywall.st
ImmunityBio Stock Surges Amid Growing Demand and Clinical Success - StocksToTrade
ImmunityBio’s Remarkable Growth: Unpacking the Surge - StocksToTrade
ImmunityBio Explores Innovations in Cancer Treatment - timothysykes.com
ImmunityBio (IBRX) Stock Forecast and Price Target 2025 - MarketBeat
ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements - simplywall.st
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com
What to know about Anktiva, the cancer drug that doesn’t use chemotherapy - NewsNation
How does nonchemotherapy cancer treatment Anktiva work? - NewsNation
Q3 2025 Contract Research Organization (CRO) Activity and Intel Report Featuring ICON, Astrazeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, and Boryung - Yahoo Finance
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue - MSN
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):